Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer response to questions on M&A -> add value to company

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Oct 19, 2022 8:15am

119 Views

Post# 35033181

RE:RE:RE:Pfizer response to questions on M&A -> add value to company

Noteable wrote: Pfizer's PD-1 immune checkpoint inhibitor (sasanlimab) currently under development - (which could potentially be combined with ONCY's pelareorep)

Sasanlimab - Aternative names: PF-06801591; PF-6801591; RN-888
Recent Events:

28 Apr 2022No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection)

15 Feb 2022Phase-II clinical trials in Bladder cancer (Neoadjuvant therapy) in USA (SC) (NCT05241340)

15 Feb 2022Pfizer plans a phase II trial for urothelial carcinoma bladder(In adults, In the elderly, Neoadjuvant therapy) in February 2022 (NCT05241340)

Using Viruses to Fight Cancer: A New Approach to Treating Solid Tumors
https://insights.pfizer.com/using-viruses-to-fight-cancer-a-new-approach-to-treating-solid-tumors/